Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. is in advanced discussions with major pharmaceutical companies for a strategic partnership on PrimeC, their lead drug candidate for treating ALS. The potential agreement promises significant financial returns for NeuroSense through upfront, milestone, and royalty payments. PrimeC has demonstrated encouraging results in clinical trials, but the finalization of any agreement remains uncertain.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
